



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,546	09/12/2006	Patrick Hanley	PA1365	4055
28390	7590	09/11/2007		
MEDTRONIC VASCULAR, INC.			EXAMINER	
IP LEGAL DEPARTMENT			PEZZUTO, HELEN LEE	
3576 UNOCAL PLACE				
SANTA ROSA, CA 95403			ART UNIT	PAPER NUMBER
			1713	
			NOTIFICATION DATE	DELIVERY MODE
			09/11/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

rs.vasciplegal@medtronic.com

Office Action Summary	Application No.	Applicant(s)
	10/553,546	HANLEY ET AL.
Examiner	Art Unit	
Helen L. Pezzuto	1713	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 17 October 2005.
2a) This action is **FINAL**. 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-14 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-14 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 17 October 2005 is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 1/23/06.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
5) Notice of Informal Patent Application
6) Other: ____.

DETAILED ACTION

Claims 1-14 are pending in this application.

Claim Objections

1. Claims 5-6, 8-9, 11 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim. See MPEP § 608.01(n).

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claim 7 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The molecular weights expressed in claim 7 are indefinite because the molecular weight for polymers should be defined by one of the standard types (i.e. MW, Mn, etc).

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the

Art Unit: 1713

differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 1-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bradford et al. (US-759) or Garnett et al. (US-511).

US 6,835,759 to Bradford et al. discloses a dual cure coating composition comprising a radiation curable component (a1), a thermally curable binder component (a2), a thermally crosslinking component (a3), and optionally one or more reactive diluents (a4). Specifically, prior art (a1) and (a2) components can be oligomeric or polymeric, having a number average molecular weight of from 500 to 50,000, defined within the scope of the one of the recited polymeric species (e.g. the relatively lower molecular weight polymer). Suitable reactive diluents (a4) include (meth)acrylic acid, alkylene glycol di(meth)acrylate, embraces the instant unsaturated hydrophilic monomer (col. 12, lines 45-62). Prior art further teaches up to 40 wt% of coating additives, including polyvinylpyrrolidone polymer, embracing one of the polymeric species defined in the present claims (e.g. the relatively higher molecular weight polymer). Photoinitiators such as benzophenone and reaction

Art Unit: 1713

solvents were further disclosed (col. 15, line 67; col. 16, lines 24-41). Accordingly, it would have been obvious to one having ordinary skill in the art to select the relatively high and low molecular weight polymeric species, the unsaturated monomer such as acrylic acid or a diacrylate, a UV activatable compound such as benzophenone, polyvinylpyrrolidone as a coating additive, and a suitable solvent to formulate a coating composition as presently claimed, motivated by the reasonable expectation of success.

Similarly, US 6,162,511 to Garnett et al. discloses a radiation curable coating composition comprising a resin component including an unsaturated monomer, and an unsaturated oligomer/prepolymer, and binder or mixture thereof (see abstract). Specifically, suitable unsaturated monomers include unsaturated carboxylic acid (e.g. acrylic acid), and multifunctional acrylate within the scope of claim 2 (col. 2, lines 34-54). Prior art oligomer or prepolymer falls within the scope of the instant relatively low molecular weight polymer. Suitable higher molecular weight binder polymer includes polyvinylpyrrolidone, encompassing the instant higher molecular weight polymer expressed in claim 14 (col. 3, lines 4-16). Hydrogen

Art Unit: 1713

abstracting photoinitiator such as benzophenone and reaction solvent were also taught (col. 3, lines 38-39; col. 4, lines 22-24). Accordingly, one having ordinary skill in the art would have readily envisage selecting the claimed components in the forming a coating composition, motivated by the reasonable expectation of success.

Regarding the "biomedical device" recited in the preamble of claim 12, the examiner takes the position that such intended use preamble language is not afforded the effect of a distinguishing limitation because the body of the claim do not set forth limitation that refers to the environment or use specified in the preamble. Thus, rendering obvious the present claims.

6. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Helen L. Pezzuto whose telephone number is (571) 272-1108. The examiner can normally be reached on 8 AM to 4 PM, Monday thru Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu can be reached on (571) 272-1114. The fax phone number for the organization

Art Unit: 1713

where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Helen L. Pezzuto
Primary Examiner
Art Unit 1713

Hlp